Work
TLY012
DR5 (TRAIL-R2) · Engineered, PEGylated trimeric recombinant human TRAIL (TNF-related apoptosis-inducing ligand); agonist of death receptor DR5 (TRAIL-R2), a tumor-selective apoptosis pathway
US Phase 1 IND cleared, per the company pipeline, with two FDA Orphan Drug Designations granted in 2020. ClinicalTrials.gov lists no TLY012 study at all (intervention search, 14 Sep 2026), so no patient dosing is on the public record. · Stalled — no completed interventional NCT
- Sponsor / originator
- Theraly Fibrosis (D&D Pharmatech)
- Current control (public)
- D&D Pharmatech / Theraly Fibrosis
- Indication
- DR5-expressing gastrointestinal cancers — pancreatic ductal adenocarcinoma and gastric adenocarcinoma in the published preclinical work. The two existing FDA orphan designations are in fibrotic disease: systemic sclerosis and chronic pancreatitis.
- Registry
- No completed NCT
1 material development may affect this asset.
Why is this asset interesting?
An IND-ready biologic with peer-reviewed oncology activity, two unused orphan designations, and no company running a cancer trial. The regulatory work was done; the trial was not. What you buy is the molecule, the IND and the ODD letters — then you run the first-in-human study in the setting the oncology data point to.
- Inferred
DR5-expressing gastrointestinal cancers — pancreatic ductal adenocarcinoma and gastric adenocarcinoma in the published preclinical work. The two existing FDA orphan designations are in fibrotic disease: systemic sclerosis and chronic pancreatitis.
- Verified
Engineered, PEGylated trimeric recombinant human TRAIL (TNF-related apoptosis-inducing ligand); agonist of death receptor DR5 (TRAIL-R2), a tumor-selective apoptosis pathway
Case file: Mechanism of action
- Inferred
Never approved, and no DR5 agonist has ever reached a US label. An engineered TRAIL with improved stability and half-life is a new product: the license is to a first-in-class molecule, its IND and its designations, not to a new use of a marketed drug.
- Inferred
Two peer-reviewed preclinical oncology studies. In gastric adenocarcinoma, ONC201/TIC10 plus TLY012 was synergistic through integrated-stress-response activation, DR5 up-regulation and loss of apoptosis inhibitors, with anti-tumor effects in organoid and xenograft models and no evidence of normal-tissue toxicity (Am J Cancer Res 2023, PMID 38187068). In an immune-competent PDAC mouse model, TLY012 10 mg/kg three times weekly plus anti-PD-1 reduced tumor growth at day 70 versus either drug alone (Am J Cancer Res 2025, PMID 39949937). Both are animal and organoid results; human DR5 agonism with this construct is untested. Earlier TRAIL-pathway drugs (dulanermin, conatumumab, tigatuzumab) failed or stalled, often on potency or PK — evidence the class is hard, not that this engineered TRAIL was tested.
- Inferred
Resurrect surfaced this class because the public record does not look like a conventional drug failure.
| Dimension | Band | Why |
|---|---|---|
| Clinical importance | High | Indication class is life-threatening or high-mortality. |
| Biological rationale | Moderate | Engineered, PEGylated trimeric recombinant human TRAIL (TNF-related apoptosis-inducing ligand); agonist of death receptor DR5 (TRAIL-R2), a tumor-selective apoptosis pathway |
| Human signal | Moderate | Public stop or trial language mentions activity, PD, or response. Confirm against CSRs; this is not verified efficacy. |
| Safety window | Unknown | No reliable public evidence identified that the therapeutic window is either intact or closed. |
| Failure recoverability | High | Potentially recoverable |
| Novelty | High | Never reached a US label on the information in this file. |
| Development leverage | Moderate | Highest public stage recorded: US Phase 1 IND cleared, per the company pipeline, with two FDA Orphan Drug Designations granted in 2020. ClinicalTrials.gov lists no TLY012 study at all (intervention search, 14 Sep 2026), so no patient dosing is on the public record.. |
| IP potential | Moderate | Composition and use hypotheses require counsel; this is not a patentability opinion. |
| Dealability | Moderate | Owner identified in the public record. Potential licensing candidate; availability is not verified. |
| Evidence quality | Moderate | 7 public source(s) attached to this file. |
Bands are ranking aids, not probabilities of technical or commercial success.
What happened?
Pre-2020
Engineered recombinant human TRAIL (DR5 agonist)
InferredDesigned for improved stability/half-life versus first-generation TRAIL ligands; claimed myofibroblast selectivity via DR5.
D&D Pharmatech pipeline: TLY012 — DR5 agonist
2020-05-28
US Orphan Drug Designation — systemic sclerosis
VerifiedTheraly Fibrosis announced US ODD for TLY012 in SSc.
Business Wire: US ODD for TLY012 in systemic sclerosis, 28 May 2020
2020
US Orphan Drug Designation — chronic pancreatitis
VerifiedSecond ODD the same year. Neither designation has a completed interventional NCT attached in this file.
Business Wire / BioSpace: US ODD for TLY012 in chronic pancreatitis, 2020
IND
US Phase 1 IND approved
VerifiedCompany pipeline lists US Phase 1 IND approved. The clinical program has not started in any meaningful public sense.
D&D Pharmatech pipeline: US Phase 1 IND approved
Current
No completed interventional NCT identified
VerifiedAbsence of a terminated registry record is a fact about the registry, not a fact that no study was ever run under another name.
Why did it stop?
Verified facts
- Verified
TLY012 has never been approved.
- Verified
Originator: Theraly Fibrosis (D&D Pharmatech). Current control (public): D&D Pharmatech / Theraly Fibrosis. Ownership requires confirmation.
- Verified
US Phase 1 IND cleared, per the company pipeline, with two FDA Orphan Drug Designations granted in 2020. ClinicalTrials.gov lists no TLY012 study at all (intervention search, 14 Sep 2026), so no patient dosing is on the public record.
Company pipeline: IND / ODD status
- Verified
Stalled translation, not a scientific kill. The designations were granted in 2020 and the pipeline still reads Phase 1 IND years later. No stop reason exists on the record because no trial was ever registered.
- Verified
No TLY012 study registered — intervention search, 14 Sep 2026
ClinicalTrials.gov: No TLY012 study registered — intervention search, 14 Sep 2026
- Verified
Parker CS … El-Deiry WS. ONC201/TIC10 plus TLY012 in gastric adenocarcinoma — ISR, DR5, apoptosis-inhibitor down-regulation; organoids and xenografts (PMID 38187068)
- Verified
Louie AD … El-Deiry WS. TLY012 plus PD-1 inhibition in an immune-competent PDAC mouse model (PMID 39949937, doi 10.62347/ROAT5658)
- Verified
Accelerated approval of dordaviprone (Modeyso) for H3 K27M-mutant diffuse midline glioma, 6 Aug 2025
- Verified
TLY012 — DR5 agonist; SSc / liver fibrosis / chronic pancreatitis; US Phase 1 IND approved
- Verified
US ODD for TLY012 in systemic sclerosis, 28 May 2020
Business Wire: US ODD for TLY012 in systemic sclerosis, 28 May 2020
- Verified
US ODD for TLY012 in chronic pancreatitis, 2020
Business Wire / BioSpace: US ODD for TLY012 in chronic pancreatitis, 2020
Resurrect analysis
- Inferred
An IND-ready biologic with peer-reviewed oncology activity, two unused orphan designations, and no company running a cancer trial. The regulatory work was done; the trial was not. What you buy is the molecule, the IND and the ODD letters — then you run the first-in-human study in the setting the oncology data point to.
- Inferred
Two peer-reviewed preclinical oncology studies. In gastric adenocarcinoma, ONC201/TIC10 plus TLY012 was synergistic through integrated-stress-response activation, DR5 up-regulation and loss of apoptosis inhibitors, with anti-tumor effects in organoid and xenograft models and no evidence of normal-tissue toxicity (Am J Cancer Res 2023, PMID 38187068). In an immune-competent PDAC mouse model, TLY012 10 mg/kg three times weekly plus anti-PD-1 reduced tumor growth at day 70 versus either drug alone (Am J Cancer Res 2025, PMID 39949937). Both are animal and organoid results; human DR5 agonism with this construct is untested. Earlier TRAIL-pathway drugs (dulanermin, conatumumab, tigatuzumab) failed or stalled, often on potency or PK — evidence the class is hard, not that this engineered TRAIL was tested.
- Inferred
No DR5 agonist is approved. Prior TRAIL-receptor programs failed on potency, PK or trial design, which says the class is hard rather than that this construct was tested. In PDAC the competition is standard chemotherapy and the KRAS-inhibitor wave; a DR5 agonist that combines with checkpoint blockade or an ISR-inducing partner is a different mechanism, not a me-too.
- Inferred
No public safety or efficacy failure exists because patients were never dosed in a reported interventional study. Capital-and-CMC is the base case until a private finding appears.
Critical unknowns
- Unknown
Why the 2020 designations never became a trial: No interventional study was ever registered, so no discontinuation reason exists. Possible causes include CMC for a trimeric protein, capital, or a private safety finding. Resolution: Ask for the IND, CMC status, any GLP toxicology and the board record around the delayed start. Treat capital and CMC as the base case until a safety finding appears.
- Unknown
Human PK and immunogenicity of this TRAIL construct: Nothing has reported in humans. Earlier TRAIL agents had short half-lives; TLY012's stability claim rests on animal data. Resolution: The first clinical study measures PK, anti-drug antibodies and a PD marker of DR5-driven apoptosis before any efficacy endpoint.
- Unknown
Whether the mouse oncology exposure translates: The PDAC work dosed 10 mg/kg three times weekly in mice. The human-equivalent dose and its tolerability are not public. Resolution: Allometric scaling plus the GLP tox package set the Phase 1 starting dose; request both before term-sheet economics.
- Unknown
Composition-of-matter and ODD transferability: An ODD is specific to the product and the indication, and does not travel automatically with a license. Resolution: Counsel on ODD transfer or a new-sponsor filing, plus chain of title on the engineered-TRAIL patents, before economics.
Is the failure recoverable?
Potentially recoverable. A recoverable category is a reason for expert investigation, not a conclusion that the drug is valuable.
Scientific barrierInferredPotentially recoverable
- What was the problem?
- Human DR5 agonism in fibrosis is untested. Oncology TRAIL-receptor programs (different molecules) have a mixed history.
- Still relevant?
- Yes. Preclinical myofibroblast selectivity must be shown in patients.
- Has knowledge or technology changed?
- No approved DR5 agonist. The class is hard; this construct has not been tested in humans.
- Evidence that would resolve it
- First-in-human PD of myofibroblast or tumor apoptosis, not a press-release mechanism.
- Experiment or diligence step
- SAD/MAD with PK, ADA and a PD apoptosis marker.
Safety barrierUnknownUnknown
- What was the problem?
- No public safety failure exists because patients were never dosed in a reported interventional study. Private GLP tox or ADA could still kill the program.
- Still relevant?
- Unknown — this is the critical unknown, not a verified clean bill.
- Has knowledge or technology changed?
- Not established.
- Evidence that would resolve it
- IND, any GLP tox, ADA risk assessment.
- Experiment or diligence step
- Make tox/ADA a 90-day option condition. If repeat dosing is untenable, pass.
Technical barrierInferredPotentially recoverable
- What was the problem?
- Prior TRAIL agents had short half-life. This construct is claimed to fix that in animals. Human PK is not reported.
- Still relevant?
- Yes until human PK exists.
- Has knowledge or technology changed?
- Engineered / PEGylated TRAIL is the differentiator on paper.
- Evidence that would resolve it
- Human PK and ADA from the first clinical study.
- Experiment or diligence step
- First clinical study is PK/ADA/PD — not a registrational fibrosis endpoint.
Formulation / delivery barrierUnknownUnknown
- What was the problem?
- Biologic delivery is not the public stop reason. Not applicable as a historical failure mode.
- Still relevant?
- Secondary to CMC of a trimeric protein.
- Has knowledge or technology changed?
- Not established.
- Evidence that would resolve it
- Clinical presentation described in the IND.
- Experiment or diligence step
- Read the IND CMC/presentation section.
CMC barrierHypothesisPotentially recoverable
- What was the problem?
- CMC for a trimeric / engineered TRAIL is a plausible reason the 2020 ODDs never became a trial. Not verified.
- Still relevant?
- Treat capital-and-CMC as the base case until a safety finding appears.
- Has knowledge or technology changed?
- Years have passed since ODD without a completed interventional NCT.
- Evidence that would resolve it
- Current manufacturing status, scale, and cost of clinical-grade material.
- Experiment or diligence step
- Request CMC status with the IND. If clinical-grade material cannot be made at a rare-disease cost, pass.
Clinical-design barrierInferredPotentially recoverable
- What was the problem?
- The clinical program has not started in any meaningful public sense. There is no failed protocol to autopsy.
- Still relevant?
- The first-patient choice (SSc-ILD vs DR5-high oncology) is the strategy.
- Has knowledge or technology changed?
- ODDs from 2020 are unused. They compress the FDA conversation only if a study is actually started.
- Evidence that would resolve it
- IND number, protocol synopsis if any, and why the SSc start slipped.
- Experiment or diligence step
- Decision memo: SSc-ILD (unused ODD) versus DR5-high pancreatic / solid tumor (higher oncology impact, no ODD yet).
Biomarker barrierHypothesisPotentially recoverable
- What was the problem?
- Myofibroblast DR5 selectivity is a preclinical claim. Human selector for an oncology expansion is not defined here.
- Still relevant?
- Yes for any oncology path.
- Has knowledge or technology changed?
- DR5 expression assays are available; whether they predict TRAIL activity is historically mixed.
- Evidence that would resolve it
- A PD apoptosis marker and, for oncology, a DR5-high enrollment rule.
- Experiment or diligence step
- Do not run an all-comer solid-tumor study as the first expansion.
Commercial barrierInferredPotentially recoverable
- What was the problem?
- A small-company stall is often capital, not a dead market. Systemic sclerosis and PDAC are both high-need.
- Still relevant?
- Commercial viability depends on CMC cost and which indication is first.
- Has knowledge or technology changed?
- No approved DR5 agonist; fibrosis apoptosis is sparsely occupied.
- Evidence that would resolve it
- Holder's willingness to option IND + ODD files.
- Experiment or diligence step
- Licensing conversation. Potential licensing candidate — availability is not verified.
IP barrierUnknownUnknown
- What was the problem?
- ODD is product-specific and does not automatically travel with a license. Composition-of-matter chain of title is not established here.
- Still relevant?
- Yes — gating before economics.
- Has knowledge or technology changed?
- Not established.
- Evidence that would resolve it
- Counsel on ODD transfer / new-sponsor ODD filing, plus chain of title on the engineered TRAIL patents.
- Experiment or diligence step
- Patent and regulatory counsel. Potential IP hypothesis — requires patent counsel and scientific validation.
Organizational barrierInferredPotentially recoverable
- What was the problem?
- Stalled translation at a small company with unused FDA designations. No public discontinuation reason exists because no interventional NCT completed.
- Still relevant?
- Yes. This is the pattern, not a verified financing collapse.
- Has knowledge or technology changed?
- Pipeline still lists Phase 1 IND-approved years later.
- Evidence that would resolve it
- Board-level reason the SSc trial did not start; any quiet trial under another name.
- Experiment or diligence step
- This week: request IND number, ODD letters, CMC status, GLP tox. If either 'IND-ready' or 'unused' is false, stop.
Where is the opportunity?
Labeled Supported / Plausible hypothesis / Requires expert validation. Speculative ideas are not stated as fact.
- Verified
Supported — deadly-illness relevance: Pancreatic and gastric adenocarcinoma are among the deadliest solid tumors, and DR5 is how TRAIL kills tumor cells while sparing most normal tissue. The published oncology work tests TLY012 in exactly those two cancers, in combination with checkpoint blockade and with an approved DR5-inducing drug. The fibrosis designations remain a second route with an FDA head start: systemic sclerosis kills through lung and pulmonary vascular disease.
- Inferred
Supported — never-approved novelty: Never approved, and no DR5 agonist has ever reached a US label. An engineered TRAIL with improved stability and half-life is a new product: the license is to a first-in-class molecule, its IND and its designations, not to a new use of a marketed drug.
- Hypothesis
Plausible hypothesis — Two peer-reviewed preclinical oncology studies. In gastric adenocarcinoma, ONC201/TIC10 plus TLY012 was synergistic through integrated-stress-response activation, DR5 up-regulation and loss of apoptosis inhibitors, with anti-tumor effects in organoid and xenograft models and no evidence of normal-tissue toxicity (Am J Cancer Res 2023, PMID 38187068). In an immune-competent PDAC mouse model, TLY012 10 mg/kg three times weekly plus anti-PD-1 reduced tumor growth at day 70 versus either drug alone (Am J Cancer Res 2025, PMID 39949937). Both are animal and organoid results; human DR5 agonism with this construct is untested. Earlier TRAIL-pathway drugs (dulanermin, conatumumab, tigatuzumab) failed or stalled, often on potency or PK — evidence the class is hard, not that this engineered TRAIL was tested.
- Hypothesis
Requires expert validation — FDA levers are directional, not a regulatory strategy: Orphan Drug Designations already held for systemic sclerosis (May 2020) and chronic pancreatitis (2020). Both are fibrosis indications and do not carry over to cancer.; A new orphan designation is realistic for a molecularly defined DR5-high gastric or pancreatic setting; Fast Track is reachable in PDAC once a first-in-human study shows a signal; Combination route: ONC201 (dordaviprone, Modeyso) received FDA accelerated approval on 6 Aug 2025, so the gastric-cancer combination would pair a never-approved DR5 agonist with an approved partner
- Hypothesis
Requires expert validation — any chemical, formulation, or use modification is a potential IP hypothesis, not a patentability opinion.
Can we get it?
Ownership
- Verified
Historical owner: Theraly Fibrosis (D&D Pharmatech).
- Inferred
Current control as recorded: D&D Pharmatech / Theraly Fibrosis. Ownership requires confirmation.
- Unknown
No molecule-level assignment document is in this file. Successor control is inferred from corporate events and pipeline pages.
- Inferred
Evidence of current development: pipeline listing only. Activity is unclear.
Licensing intelligence
Potential licensing candidate — not “available for licensing.”
- Hypothesis
Potential licensing candidate. Do not read this as 'available for licensing'.
- Hypothesis
Who to contact: BD / out-licensing for D&D Pharmatech / Theraly Fibrosis, specifically discontinued or stalled clinical assets.
- Unknown
No public evidence in this file that the asset has already been licensed. Absence of a press release is not proof it is unencumbered.
- Hypothesis
Diligence documents to request: IND, ODD letters, CMC status, GLP tox, chain of title, any quiet trial.
IP opportunity
Existing patents
- Unknown
Engineered TRAIL composition families are expected; specific publication numbers are not verified in this file.
- Hypothesis
This is not patent counsel and not an FTO opinion.
Potential new IP
Potential IP hypothesis — requires patent counsel and scientific validation.
- Hypothesis
Potential IP hypothesis — requires patent counsel and scientific validation.
- Hypothesis
Manufacturing methods for a stable trimeric TRAIL — could matter if CMC is the stall; prior art likely dense.
- Hypothesis
Biomarker-selected oncology use (DR5-high) — method-of-treatment hypothesis; ODD for SSc does not cover it.
- Hypothesis
Combination with standard fibrosis or PDAC regimens — speculative; requires expert validation.
What should we do next?
| Priority | Action | Why it matters | Uncertainty resolved | Evidence |
|---|---|---|---|---|
| High | Request the IND number, ODD letters, CMC status and any GLP toxicology from D&D Pharmatech / Theraly. Pull the dosing, schedule and toxicity observations from PMIDs 38187068 and 39949937. | The thesis is 'IND-ready, active in animal oncology models, unused'. If the IND or the tox package is not there, stop. | Counterparty, package existence, and whether the thesis is even optionable. | Owner correspondence and document index |
| Medium | Option for the TRAIL construct plus both ODD files. Decide the first cohort: DR5-high pancreatic or gastric cancer (with anti-PD-1 or dordaviprone as the combination arm), versus SSc-ILD under the existing designation. | That choice is the medical and FDA strategy. Oncology carries the higher impact; fibrosis carries the designation already in hand. | Whether the historical limitation is solvable with a finite experiment. | Primary data package / experiment |
| Low | If CMC and tox clear: first-in-human SAD/MAD with PK, anti-drug antibodies and a DR5-apoptosis PD marker; pre-IND or Type B meeting on the oncology expansion, and a new orphan request for the chosen tumor. | The fastest FDA path starts with a clean human PK/PD readout. The fibrosis ODDs only help if that indication is pursued; a cancer program needs its own. | Whether the historical limitation is solvable with a finite experiment. | Primary data package / experiment |
| High | Pass immediately if a mechanism-based safety finding or an already-licensed exclusive third party appears in the first document drop. | Those are falsifiers, not diligence items to admire. | Whether the file is dead before spend. | Safety listings / license grant |
Material developments
2020
What changed
Two US ODDs granted; years later the pipeline still lists Phase 1 IND-approved with no completed interventional NCT.
Why it matters
Unused FDA head start plus no public scientific failure is the stall pattern, not a verified kill.
Which conclusion may need review
Whether the IND is still live, whether ODD files transfer, and why the trial never started.
Advance to diligence
Generates an editable Asset Acquisition & Development Dossier (28 sections) a BD or translational lead can take into a licensing conversation. Saved to Library.